IL1B and COVID-19: In addition, the hyperinflammatory state in COVID-19 is reported to resemble some aspects of hemophagocytic lymphohistiocytosis (HLH), a condition that may benefit from therapeutic IL-1β blockade (Mehta et al., 2020).